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ABSTRACT
Meagan Elizabeth Buchanan: Interactions of Fentanyl with gp120 in the Central Nervous
System
(Under the direction of Dr. Jason Paris)
The Human Immunodeficiency Virus (HIV) has affected more than 75 million
individuals worldwide. HIV not only affects the peripheral system through the targeting
of T cells, but also causes adverse effects in the central nervous system. Individuals
suffering from HIV often experience neuropathic pain and are prescribed opioids to
combat the chronic pain. Along with the increase of opioids prescribed to HIV patients,
the number of deaths related to the synthetic opioid, fentanyl, has increased drastically.
Drug abuse and HIV are interlinked epidemics; individuals who are HIV positive and
referred to as “NeuroAIDS.” The HIV envelope protein, gp120, has been shown to have
a wide variety of neurotoxic effects on the CNS through increasing cell death of
astrocytes through stress-mediated apoptosis, increasing the permeability of the Blood
Brain Barrier (BBB), increasing the expression of proinflammatory cytokines and
chemokines, and altering and damaging mitochondria. The purpose of these
experiments was to determine whether gp120 showed direct neurotoxic effects and/or
indirect neurotoxic effects and whether fentanyl would act synergistically with gp120.
Through conducting a Live/Dead Assay, Immunocytochemistry for GFAP/IBA1, and a
Cytokine Array, it was determined that gp120 shows neither direct nor indirect
neurotoxic effects, and fentanyl does not exacerbate the effects of gp120.
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1. Introduction:
a.

HIV worldwide and in the U.S.
The human immunodeficiency virus (HIV) epidemic has infected more than 75

million people worldwide since the first reported cases in 1981, and an estimated 35
million people have died due to complications associated with HIV (“HIV/AIDS,” 2018).
Currently, there are approximately 37 million individuals living with the infection (Deeks,
et al., 2015); roughly 26 million of these individuals live in Sub-Saharan Africa, (Kharsany
& Karim, 2016) and approximately 1.1 million people live in the United States,
accounting for an estimated 162,500 who are unaware of their condition (“Drug Use and
Viral Infections,” 2018). In Sub-Saharan Africa, HIV is most prevalent among women
aged 15-24 due to cultural interactions (CDC). In the United States, the populations
most affected by HIV are homosexual African American men and homosexual
Hispanic/Latino men; both populations have experienced an increase in HIV diagnoses in
recent years, whereas all other populations have experienced a decrease in diagnoses
(“Estimated HIV Incidence and Prevalence in the United States,” 2018).
b.

HIV transmission
HIV is transmitted from infected individuals through bodily fluids: blood, semen,

pre-seminal fluid, anogenital fluids, and breast milk. Transmission occurs via viral
contact with mucus membranes, tissue lesions, or via direct transmission into the blood

stream, such as occurs with injection drug use (“HIV/AIDS,” 2018). Individuals
who inject drugs, hormones, steroids, or silicone can acquire HIV by sharing needles,
syringes, or other injection equipment due to residual blood from an infected person.
Additionally, the virus can survive within used injection equipment for up to 42 days,
depending on environmental conditions (“HIV/AIDS,” 2018). The contribution of
increased engagement in risky sexual behavior associated with impaired judgment
associated with drug use is also a consideration (“HIV/AIDS,” 2018).
c.

HIV effects on the body
HIV affects all organ systems in the body through its interactions with the

immune system. HIV targets T cells and reduces cell-mediated immunity which leads to
severe opportunistic infections and cancers. HIV infects and eradicates CD4+ T-cells, or
helper T-cells. CD4+ T-cells mature in the thymus of the human body and aid B cells in
the production of antibodies, induce macrophage activity, recruit neutrophils,
eosinophils, and basophils to infection and inflammation sites, and produce cytokines
and chemokines (Zhu & Paul, 2008). Cytokines and chemokines are secreted, small cellsignaling protein molecules, whose receptors are expressed on immune cells. These
factors play a critical role in immune cell differentiation, migration, and polarization into
functional subtypes and in directing their biological functions (Shachar & Karin, 2013).
d.

HIV and injecting drug users (IDU)
While Sub-Saharan Africa contains 70% of the world’s population of HIV positive

individuals, the main route in that region is heterosexual transmission (Aceijas et al.,
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2004). However, in China, Indonesia, Vietnam, several Asian republics, the Baltic States,
and North Africa the main route of transmission is primarily unsafe drug-injecting
practices with additional HIV spread occurring through commercial sex work (Aceijas et
al., 2004). Additionally, it is estimated that in many countries in Europe, Asia, the Middle
East, and the Southern Latin America, the sharing of injecting equipment is the primary
mode of transmission, accounting for 30–90% of all reported infections (Aceijas et al.,
2004).
In the United States, injection drug use is associated with approximately onethird of all HIV infections, and approximately 10% of all new HIV diagnoses are
attributed to injection drug use or male-to-male sexual contact and injection drug
use (“HIV/AIDS,” 2018). Research has estimated that HIV positive IDU might significantly
contribute to higher rates of transmission even when compared to those with
ineffective or inconsistent treatment (Escudero, et al., 2017).
Even though awareness of transmission of HIV is at an all-time high in the United
States, the prevalence of illegal opioid drug use also continues to climb. As a result,
multi-person sharing of needles continues to be a common occurrence. To combat the
transmission of HIV and other diseases through infected needles, the United States
established the Syringe Service Programs (SSPs). SSPs allow individuals to exchange used
syringes for sterile syringes; this has shown to decrease the spread of HIV, while not
increasing the prevalence of illegal drug use (“Syringe Services Programs,”
2018). Additionally, even with the establishment of a treatment protocol for HIV, called
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cART, HIV positive individuals with transmission via IDU continue to experience shorter
lifespans (Marcus, et al., 2016).
e.

Opioid toxicity
The most commonly injected drugs are opioids; the most abused opioid is heroin

(Baciewicz, 2012). Chronic opioid use leads to multiple impairments in the central
nervous system: increased microglial activation, increased axonal damage, increased
neuronal loss, increased vasculopathy, and decreased astrocytes. Additionally, chronic
opioid use has been shown to cause dizziness, sedation, hyperalgesia associated with
increased sensitivity to pain, and increased rates of clinical depression and other mental
illnesses (Arts & Hazuda, 2012).
f.

Opioids and HIV
While the mechanisms in which opioids contribute to the increased

neurocognitive impairments are not completely understood, the regulation of immune
cell functions is thought to play a role (Jaureguiberry-Bravo, et al., 2018). Studies have
shown that opiate abuse may act at multiple glial-cell types to further compromise
neuron function and survival (Hauser, et al., 2012). Opioids also allow easier access to
HIV to enter the brain by weakening the blood brain barrier (BBB) and cause greater
nerve cell injury (“Opioid Overdose Death Rates,” 2018). Additionally, opioids potentiate
the effects of HIV by promoting the progression to Acquired Immunodeficiency
Syndrome (AIDS), increasing the frequency and severity of HIV encephalitis, and
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potentiating the symptoms of HIV Associated Neurocognitive Disorder (HAND)
(Jaureguiberry-Bravo, et al., 2018).
g.

The effects of fentanyl
From 2002-2017, there was a 4.1-fold increase in the total number of opioid

overdose related deaths and a 900% increase in the number of individual seeking
treatment for prescription opioid abuse (Kolodny A, et al., 2015). In 2016 alone, more
than 42,000 individuals in the U.S. died from opioid overdoses – more than 115 per day
– and synthetic opioids were involved in approximately 50% of overdoses (“Opioid
Overdose Death Rates,” 2018). The most commonly used synthetic opioid was fentanyl;
from 2002-2017, there was a 22-fold increase in the total number of deaths due to
fentanyl (“Fentanyl and Other Synthetic Opioids Drug Overdose Deaths,” 2018).
Fentanyl is approximately 50 times more potent than heroin and 100 times more potent
than morphine and negates naloxone, an opioid antagonist that reverses and blocks the
effects of opioids (“Opioid Overdose,” 2016). It is because of these reasons that fentanyl
is driving the opioid epidemic.
h.

HIV patients and pain
Due to the neuropathic properties of HIV, over 50% of HIV patients suffer from

chronic pain and are often prescribed opioids to combat the pain (Liu, Bolong et al.,
2016). Studies show that opioids exacerbate the negative effects of HIV on the nervous
system by promoting damage of the neurons, activation of caspase dependent and
independent pro-apoptotic pathways, and disruption of glial functions; opioids can also
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activate glial cells, such as microglia and astrocytes (Liu, Bolong et al.,2016). The
activation of glial cells may facilitate the expression of hyperalgesia by releasing
cytokines, chemokines, and brain-derived neurotrophic factor (Liu, Bolong et al., 2016).
i.

NeuroAIDS
Drug abuse and HIV are interlinked epidemics; individuals who are HIV positive

and abuse drugs show more severe symptoms of neurocognitive impairments linked to
HIV, sometimes collectively referred to as “NeuroAIDS.” Since the development of
combined antiretroviral therapy (cART) in 1996, the number of deaths due to HIV has
decreased and individuals are able to live longer with the infection (Saylor, et al., 2016).
cART aids in counteracting progression of HIV in the peripheral nervous system but
cannot accumulate in the central nervous system due to its inability to permeate the
blood brain barrier (Kumar, et al., 2018). Due to the increase of life expectancy, HIVinfected patients now contend with more neurocognitive impairments: mood disorders,
cognitive impairment, behavioral disinhibition, motor impairment, and peripheral
neuropathies associated with HIV patients (Saylor, et al., 2016). These neurocognitive
impairments, which affect approximately 50% of all HIV patients, have been deemed as
HIV Associated Neurocognitive Disorder (HAND) (Arts & Hazuda, 2012). Three categories
of HAND have been discovered by researchers: Asymptomatic Neurocognitive
Impairment (ANI), Mild Neurocognitive Disorder (MND), and HIV Associated Dementia
(HAD) (Arts & Hazuda, 2012). Individuals who suffer from ANI show no impairment in
activities of daily living (Arts & Hazuda, 2012) but show HIV associated cognitive
impairment of at least two cognitive areas, such as memory, processing speed,
6

attention, sensory perceptual and motor skills (Kumar, et al., 2018). Individuals who
suffer from MND show impairment in activities of daily living (Arts & Hazuda, 2012) with
a decline in brain function, movement skills, and shifts in behavior (Kumar, et al., 2018).
Individuals who suffer from HAD show marked impairment in activities of daily living
and include individuals who suffer from HIV associated dementia and HIV-encephalitis, a
neuro-inflammatory condition characterized by the presence of activated and infected
microglia, multinucleated giant cells, astrogliosis, and loss of myelin (Saylor, et al.,
2016). cART has successfully decreased the severity of HAND, but not the prevalence;
the majority of individuals that are HIV positive now live with HAND but suffer from the
less severe types (Saylor, et al., 2016). Additionally, HIV positive individuals with
transmission via IDU have shorter lifespans even with the addition of cART (Festa &
Meucci, 2012).
j.

HIV envelope protein gp120 and its effect on NeuroAIDS
The HIV protein gp120 is a highly glycosylated envelope protein that assists with

viral entry into the cell through a conformational change in CD4 and a g-protein coupled
receptor (GPCR) (Rich et al., 2019). While CD4 is necessary for viral entry, it is not
sufficient, and HIV requires an additional interaction with GPCR chemokine coreceptors. Through the binding of viral glycoproteins and cell surface glycoproteins the
process of adsorptive endocytosis begins. Broadly, HIV often parsed into three primary
strains X4, R5, and a dual X4 and R5 strain, albeit, additional strains exist, particularly in
world regions with poor virulence control. These strains are determined by the
selectivity of the gp120 molecule for a particular co-receptor, called a “tropism” (Rich et
7

al., 2019). In X4-tropic strains, gp120 is associated with the CXCR4 chemokine receptor,
and in R5-tropic strains, gp120 is associated with the CCR5 chemokine receptor (Rich et
al., 2019). The CXCR4 co-receptor is the C-X-C motif chemokine receptor 4 and is one of
the chemokine receptors expressed primarily on T-cells (Charo et al., 2018). In the
periphery, CXCR4 plays a role in cell migration and acts as a receptor for extracellular
ubiquitin by increasing intracellular calcium ion levels (“C-X-C Chemokine Receptor Type
4,” 2018). The CCR5 co-receptor is the C-C motif chemokine receptor 5 and is one of the
chemokine receptors expressed on multiple cell types, including macrophages and some
types of T-cells (Woollard & Kanmogne, 2015). R5 strains predominate in early stages of
HIV infection, and X4 strains emerge in later stages (Woollard & Kanmogne, 2015).
Gp120 has been shown to have a wide variety of neurotoxic effects on the CNS.
Gp120 increases cell death of astrocytes through stress-mediated apoptosis (Shah et al.,
2012). Additionally, gp120 alters the BBB by increasing the permeability; the BBB aids in
proper functioning and homeostasis of the CNS by regulating the trafficking of
molecules (Shah, Ankit et al.). Gp120 increases the expression of proinflammatory
cytokines and chemokines which promotes leukocyte chemotaxis to inflammation sites
(Charo et al., 2018). Although the mechanisms are not fully understood, gp120 enlarges
and damages mitochondria and impairs the transport of mitochondria along
microtubules (Avdoshina et al., 2016). Gp120 also inhibits microtubule polymerization
and tubulin acetylation, which results in impaired axonal function (Avdoshina et al.,
2017). These findings suggest that the mechanism of gp120 neurotoxicity is contributed
to the detrimental effects on microtubules.
8

k.

Hypothesis
To determine if gp120 was directly neurotoxic, we exposed differentiated human

neuroblastoma cells to X4-gp120 and/or R5-gp120 (10 – 1000 pM). To assess the extent
to which gp120 exerted indirect toxicity via neuroinflammation, in the absence or
presence of an abused opioid, primary mixed glia were obtained from mice and exposed
to X4- or R5 gp120 (500 pM) with or without co-exposure to fentanyl. We hypothesized
that gp120 would show both direct and indirect neurotoxic effects and fentanyl would
potentiate these effects.
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2.

Methods
2.1 Description of Cells and Cell Culture Processes
a. SH-SY5Y human neuroblastoma cells
An SH-SY5Y cell line was received from the American Type Culture
Collection (ATCC; Manassas, VA). Cells were relocated from growth flasks into 24
well plates and allowed to grow in media (DMEM/F12 89.5%, Fetal Bovine Serum
10%, Antibiotic (PSF) 0.5%) in an incubator kept at 37°C and 5% CO2. Once the
cells were at 50% confluency, Retinoic Acid (50 mG retinoic acid, 33.3 mL 95%
EtOH) was added to begin differentiation. After ~6 days, BDNF (10 µG BDNF, 1
mL DMEM/F12) was added to continue differentiation. Throughout the
differentiation process, a full media exchange occurred every 48 hours and
plates were kept in an incubator (Paris et al., 2019).
b. Primary mouse mixed glia cells
Primary mixed glial cultures were prepared as previously described (Paris
et al., 2016). Briefly, mixed-glia were obtained from the whole-brain postnatal
day 0–1 C57BL/6HNsd. Brains were minced before being incubated (37˚C, 5%
CO2) with trypsin (2.5 mg/ml) and DNase (0.015 mg/ml) in Dulbecco’s Modified
Eagle’s Medium (DMEM; Life Technologies, Carlsbad, CA) for 30 min. Tissues
were triturated and sequentially filtered through 100-µm and 40-µm diameter
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pore cell strainers (Greiner Bio-One, Kremsmünster, Austria). Cells were
plated at a density of 150,000 cells/well onto poly-L-lysine-coated (Sigma–
Aldrich, St. Louis, MO) 24-well culture plates and maintained for 11-14 days in
DMEM supplemented with 10% fetal bovine serum (Thermo Scientific Hyclone,
Logan, UT). The mixed glial cells were harvested from 0-2 day old C57 BL/6HNsd
pups and were seeded on 24- well plates at a density of 150,000 per well (Paris
et al., 2016).
2.2 Experimental Procedures
a. Live/Dead Assay
After the SH-SY5Y cells were grown to 80% confluency and seeded onto a
24-well plate at a density of 50,000 cell/well, gp120 X4 and gp120 R5 received
from ImmunoDX (Woburn, MA) were used to treat the cells. X4-gp120 and/or
R5-gp120 were used at concentrations of 0, 10, 100, and 1000 pM. Fluorescents
were added to the wells by mixing the fluorescents with the gp120 treatments or
media per the controls. A master mix of propidium iodide/DAPI was created with
gp120 media (one drop of propidium iodide/DAPI was added per mL of gp120
treatments/media) at time 0 and the number of red positive cells were counted
at 0, 24, and 48 hours, but the cell death reached over 60% at 48 and no group
differences were observed as such and only hours 0-24 were used for analyses.
Propidium iodide is a membrane impermeable dye that only stains the DNA of a
cell if the membrane is compromised. DAPI is a membrane permeable dye that
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stains the DNA in all cells. By comparing those that were propidium iodide
stained and the total number of cells, the percent of dead cells was determined.
b. Immunocytochemistry for GFAP/IBA1
Wells were treated with gp120 X4 or gp120 R5 at a concentration of 500
pM, as well as fentanyl was obtained from: Sigma Aldrich (St. Louis, MO; #F-013)
diluted to final concentration in media at 1 µM. 24 hours later, cells were fixed in
4% Paraformaldehyde. Permeability solution (0.1% Triton X 100, 0.1% Bovine
Serum Albumin in PBS) was added to each well and incubated at room
temperature for 30 minutes. Then the permeability solution was removed and
blocking solution (1% Bovine Serum Albumin, 1% Normal Goat Serum in PBS) was
added to each well and incubated at room temperature for 30 minutes. Blocking
solution was removed and primary antibodies, (Wako (Richmond, VA) anti-Iba 1
Milipore (anti-gfap) mab360 Burlington, MA 1:250 dilution in Blocking Solution)
were added to each well and incubated overnight in a 4°C moisture chamber.
The next day, the primary antibodies were removed, and the wells were washed
with PBS 3 times for 10 minutes each. Secondary antibodies (Alexafluor 594 and
488 (Carlsbad, CA) 1:500 dilution in Blocking Solution) were added to the wells
and incubated in the dark for one hour at room temperature. After an hour, the
secondary antibodies were removed, and the wells were washed with PBS 3
times for 10 minutes each. Hoechst 33342 (1:10,000 dilution in PBS) was added
to each well and incubated at room temperature in the dark for 8 minutes. The
Hoechst was removed, and the wells were washed with PBS 3 times for 10 mins
12

each. The plates were kept in the dark until ready to be imaged by a Nikon Ti2
microscope. By using Image J software, the number of microglia were counted
and integrated density of astroglia was calculated. Microglia were counted by
selecting a random field with at least 200 cells per field and determining the
number Hoechst positive cells and the number of Iba-1 positive cells. To
determine the integrated density of astroglia, the images were uploaded to
ImageJ and a threshold was developed to distinguish signal from the
background. From the signal, Image J software was able to determine the
intensity and the area. Integrated density was determined by calculating the
mean intensity of signal multiplied by the total area of signal.
c.

Cytokine array
Proteome Profiler Antibody Array: Mouse Cytokine Array Panel A ary-006

was purchased from R&D Systems, Inc. Minneapolis, MN and the array protocol
for cell culture supernatants was performed according to manufacturing
recommendations. To determine levels of mouse chemokines and cytokines, cell
culture supernatants were placed on pre-coated membranes to determine the
level of cytokine activity in cell supernatants for 38 cytokines. These cytokines
included pro-inflammatory cytokines (TNFa, IFNg, IL-1a, IL-1b, IL-2, IL-3, IL-6, IL-7,
IL-12p70, IL-16, IL-17, IL-23, and IL-27), anti-inflammatory cytokines (IL-1ra, IL-4,
IL-5, IL-10, and IL-13), and chemotactic/regulatory cytokines (C5, G-CSF, GM-CSF,
TIMP-1, TREM-1, CD54, CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL12, CCL17,
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CXCL1, CXCL2, CXCL9, CXCL10, CXCL11, and CXCL13). Images of the membranes
were taken, and level of intensity was determined on a LI-COR imager.
d. Statistical analyses
Dependent measures for Live/Dead analyses were via separate, one-way
Repeated Measures ANOVAs with gRp120 concentration as the betweensubjects factor (0, 10, 100, and 1000 pM) and time as the within-subjects factor
(0 or 24 h post-treatment). Dependent measures for immunocytochemical
endpoints were assessed via separate, two-way ANOVAs with gp120 condition
(control, X4, or R5) and fentanyl condition (vehicle or fentanyl) as betweensubjects factors. Fisher’s Protected Least Significant Difference post hoc tests
determined group differences following main effects. Interactions were
delineated via simple main effects and main effect contrasts with alpha
controlled for multiple comparisons. Analyses were considered significant when
p < 0.05.
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3. Results
3.1 Live/Dead Assay
To determine if direct neurotoxicity was present, SH-SY5Y human
neuroblastoma cells treated with X4-gp120 and or R5-gp120 (0, 10, 100, or 1000
pM) were maintained in media containing DAPI and propidium iodide and
imaged at 0, 24, and 48 hours. After 48 hours, there were no group difference
between percent cell death (data not shown). There was a significant interaction
[F(3,4)=3.59, p<.05)] from 0 to 24 hours such that X4-gp120 decreased cell death
at 10 pM (Fig. 1A). Although cell death increased from 0 to 24 hours, there was
no significant interaction between treatment conditions of R5-gp120 (Fig. 1B)
and X4/R5-gp120 (Fig. 1C) (0, 10, 100, or 1000 pM) from 0 to 24 hours.
3.2 Immunocytochemistry for GFAP/IBA1
To determine if indirect neurotoxicity was present and if fentanyl
exacerbated the effect, primary mouse mixed glial cells were treated with X4gp120 or R5-gp120 (500 pM) with and without the presence of fentanyl.
Although a decrease in frequency for microgliosis (Fig. 2A) and integrated
density for astrogliosis (Fig. 2B) were both present, there was no significant
interaction within groups.
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3.3 Cytokine Array
To determine if neurotoxicity was present and if fentanyl exacerbates the
effect through the influence of cytokines or chemokines, cell supernatant from
the primary mouse mixed glial cells that were treated with X4-gp120 or R5gp120 with and without the presence of fentanyl were taken and used on a
cytokine/chemokine array. Although fentanyl caused an increase of the
chemokines CXCL10 and CCL2 (Fig. 3A), the data did not reach significance.
Additionally, there were no significant interactions concerning any cytokines
(Fig. 3B) or individual interactions with either X4-gp120 or R5-gp120 (Fig. 3A/B).
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4.

Discussion
The expectations of these experiments were that gp120 would show both direct

and indirect neurotoxic effects through increasing cell death, astrogliosis, microgliosis,
and the presence of cytokines and chemokines. Additionally, it was expected that
fentanyl would act synergistically with gp120 and exacerbate the effects. The live/dead
assay showed a significant decrease in cell death of X4-gp120 at 10 pM from 0 to 24
hours; however, all other data were not significant. Due to the lack of direct
neurotoxicity, indirect neurotoxicity was expected to occur through astrogliosis and
microgliosis. Immunocytochemistry for GFAP and IBA1 did not
reveal significant differences, but there was an apparent effect. To assess whether
innate immune modulators were influenced, a cytokine array was performed. Fentanyl
had an apparent effect with the chemokines CXCL10 and CCL2, but these data were
exploratory (n=2/group) and groups did not significantly differ. Although the findings
were intriguing, they did not reach significance and the original hypothesis
was rejected.
Previous literature has proposed direct neurotoxicity to neurons through gp120
initiating the release of a glutamatergic excitotoxin from infected microglia and
macrophages (Howard et al., 1999). The agent reacts with NMDA receptor and calciumdependent excitotoxic damage to neurons through calcium mobilization (Howard et al.,
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1999). Calcium mobilization causes a downstream reaction in which the generation of
reactive oxygen species (ROS) and lipid peroxidation occur (Howard et al., 1999). The
exact mechanism in which the gp120 mobilized calcium causes accumulation of ROS is
unknown; however, accumulation has been shown to occur in both neurons and glia
(Howard et al., 1999). Accumulation of ROS in neurons is consistent with the proposal of
gp120 activating NMDA-dependent pathways, whereas ROS in glia indicate that gp120
mobilizes cytosolic calcium within astrocytes (Howard et al., 1999).
Additionally, gp120 has been shown to have direct neurotoxic affect through
alterations in mitochondrial fusion/fission and mitochondria biogenesis (Fields et al.,
2016). Mitochondrial fusion is dependent on MFN1, MFN2, and OPA1; mitochondrial
fusion is dependent on DRP1 (Fields, et al.). Experiments have shown levels of MFN1,
OPA1, and DRP1 were altered in the brains of HAND patients and in gp120 transgenic
mice (Fields et al., 2016). Additionally, gp120 transgenic mice showed damaged
mitochondria and increased markers of neuroinflammation (Fields et al., 2016).
Furthermore, the G protein coupled receptor CXCR4 and its endogenous ligand
CXCL12 have been shown to play a role in neuronal proliferation, maturation, survival,
and the regulation of dendritic spine density (Festa & Meucci, 2012). Both CXCR4 and
CXCL12 are constituently expressed in the human brain and CXCL12 has been shown to
dictate neuronal survival, neuronal transmission, and alter excitotoxic pathways (Festa
& Meucci, 2012). Disrupting the connection between CXCR4 and CXCL12 has negative
impacts within the brain. Through the cleavage of CXCL12, the neuroprotective function
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of CXCR4 is impaired and an alternate receptor, CXCR3, is activated and causes neuronal
injury (Festa & Meucci, 2012).
As gp120 binds to CXCR4, MAP kinases are activated and CXCR4 internalization
and dimerization is induced (Festa & Meucci, 2012). Gp120 then induces pathways
associated with apoptosis, such as p38 and caspase-3, even in the absence of glia and
CXCR4 internalization (Festa & Meucci, 2012). Additionally, gp120 has been shown to
directly interact with neurons through experimentation that proved CXCL12, CXCR4
inhibitors, and Gi-signaling inhibitors all reduced or blocked gp120-induced
neurotoxicity (Festa & Meucci, 2012).
Although these experiments did not match what was seen in previous literature,
several features could have played a factor. For example, receiving gp120 from different
manufacturers could have resulted in different results due to different amounts of
glycosylation. After using the enzyme PNGase F to deglycosylate gp120, our lab has
observed toxicity increased between 6-10% in a concentration-dependent manner.
Additionally, the present experiment used SH-SY5Y cells that were differentiated in
BDNF which may have been protective. Assessing different cell types could show
different direct toxicity profiles as well as potential regional vulnerability via the
assessment of primary cells from selected brain regions as opposed to those obtained
from the whole brain as was done herein. As well, In lieu of time-lapse microscopy,
propidium iodide was added at T0; due to unexpected toxic properties of propidium
iodide, it caused an increase in cell death which may have masked our capacity to

19

see effects. In future experiments, the use of time-lapse microscopy or an end point
analysis where cell death is measured at 24 or 48 would be beneficial. Lastly, cytokine
arrays were informative, but revealed targets that were semi-quantitative; more
observations are needed, and future studies will replicate the work and employ an ELISA
on targets of interest, CCL2 and CXCL10.
Future avenues of research include determining the relationship of other HIV
proteins, such as Tat and Vpr, that contribute to neurotoxicity and opioids. Tat, or the
transactivator of transcription, has been linked to progressive neuronal deregulation
that leads to the development of HAND and accelerated brain aging (Bagashev & Bassel,
2013). Tat increases the expression of chemokine receptors, induces cytokine release,
induces oxidative stress, attracts monocytes, and promotes immune cell permeation
across the BBB (McRae, 2016). Vpr plays an important role in the rate of viral replication
and the effects of the viral on T cells; however, the most detrimental characteristic of
Vpr is that it allows the replication of HIV within macrophages (Gonzalez, 2017).
While women account for 52% of all HIV infections worldwide and women aged
10-24 are twice as likely as men the same age to acquire an HIV infection (CDC), men are
more likely to die due to an HIV infection (Maskew, et al., 2013). Women typically
represent a higher CD4 count when compared to men while participating in cART
(Maskew, et al., 2013). CD4 count is strongly associated with mortality in HIV patients;
individuals with higher CD4 counts are less like to die (Lawn et al., 2008). While women
are more susceptible to acquiring an HIV infection, there is higher immune activation in
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women than men and women are less likely to progress as quickly to NeuroAIDS when
compared with men (Griesbeck et al., 2016)
One of the hypotheses as to why women are less likely to progress to NeuroAIDS
as quickly is the presence of female hormones. Recent studies have shown that both
progesterone and allopregnanolone (AlloP) show neuroprotection when administered
to animals with acute brain injury (Paris, et al., 2016). Researchers hypothesize that
progesterone and AlloP protect neurons by suppressing the inflammatory
response (Paris, et al., 2016). While progesterone and AlloP show protection, neither
show evidence of enhanced proliferation or migration (Paris, et al., 2016).
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Figure 1A: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM
of X4-gp120 from 0 to 24 hours. There was a significant interaction [F(3,4)=3.59, p<.05)]
from 0 to 24 hours such that X4-gp120 decreased cell death at 10 pM.

Figure 1B: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM
of R5-gp120 from 0 to 24 hours. There were no significant interactions between
treatment conditions.
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Figure 1C: Percent cell death of SH-SY5Y cell line treated with 0, 10, 100, and 1000 pM
of X4/R5-gp120 from 0 to 24 hours. There were no significant interactions between
treatment conditions.

Figure 1D: Image of SH-SY5Y cell line stained with cell-permanent Hoechst and cellimpermanent Propidium Iodide stains.
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Figure 2A: Frequency of microglia was determined by selecting a random field
containing at least 200 cells and counting the number of Hoechst positive cells and Iba-1
positive cells. Although a decrease in frequency was present, there was no significant
interaction within groups.

Figure 2B: Image of microglia (20X) stained with Ionized Calcium Binding Adaptor
Molecule 1 (Iba-1) and the nucleus of the cell was stained with Hoechst.
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Figure 2C: Integrated density of astroglia determined through ImageJ software by
calculating the mean intensity of signal multiplied by the total area of signal. Although a
decrease in integrated density was present, there was no significant interaction within
groups.

Figure 2D: Image of astrocytes (40X) stained with Glial Fibrillary Acidic Protein and
nucleus of the cell stained with Hoechst. Images were used to develop a threshold that
would distinguish signal from the background. From the signal, Image J software was
able to determine the intensity and the area.
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Relative Fluorescent Units
Relative Fluorescent Units

Figure 3A: Cytokine activity was determined by measuring the levels of fluorescent units
from the mixed glial cell supernatant on a cytokine array panel.

Figure 3B: Chemokine activity was determined by measuring the levels of fluorescent
units from the mixed glial cell supernatant on a cytokine array panel.
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Figure 3C: Cytokine Array Panels determine the level of mouse chemokines and
cytokines produced by mixed glial cells. Intensity levels were determined by a LI-COR
software.
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